Small Cell Lung Cancer

P3, N=200, Recruiting, NRG Oncology | Trial primary completion date: Jul 2028 --> Jun 2026

P2, N=13, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=27 --> 13

Herein, we report the first documented case of phenotypic conversion to SCLC in a patient with advanced pulmonary sarcomatoid carcinoma (PSC) who received pemetrexed, carboplatin, and camrelizumab only, with no targeted agents administered. TP53 and RET mutations may be implicated in this phenotypic transition. This case provides new insights into the biological mechanism underlying the evolution of PSC to SCLC.

P=N/A, N=20, Recruiting, The First Affiliated Hospital of Xiamen University

Postoperative circulating tumor DNA was negative, and the patient was placed on active surveillance; however, neurological symptoms persisted, and immunomodulatory therapy access was initially limited. This case highlights a rare association between anti-Hu-associated myeloneuropathy and early-onset colon cancer and underscores the importance of malignancy evaluation in unexplained sensory neuronopathy.

NCAPG promotes metabolic reprogramming in SCLC by sustaining coupled glycolytic and glycerophospholipid flux, thereby supporting tumor energy production and biosynthetic demands. Targeting this NCAPG-mediated metabolic axis may represent a promising therapeutic strategy for small-cell lung cancer.

P1, N=24, Active, not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting | N=48 --> 24 | Trial primary completion date: Sep 2025 --> Sep 2027

Integrin β1 is a key mediator of Laminin's pro-tumorigenic effects in SCLC. Curcumol disrupts Laminin-Integrin β1 interaction, inhibits FAK/ERK signaling and EMT, and suppresses tumor progression, representing a promising therapeutic strategy.

The SCLC component dictated adjuvant cisplatin-etoposide regardless of the accompanying adenocarcinoma histology. This case report exemplifies the importance of integrated histologic and molecular evaluation, and the need to recognize potentially actionable mutations in combined SCLC. Comprehensive profiling not only clarifies clonal relationships and may guide therapeutic strategies, including in the context of recurrence or combined presentations.

Expansion of Ki67+ and ICOS+ (p=0.0024; 0.0074) CD8+ T cells was also observed in CD8+ T cells from long survivors exclusively from cohort 2. This study provides one of the few longitudinal assessments of peripheral immune dynamics in SCLC patients receiving ICBt, suggesting that early on-treatment changes, evaluated relative to each patient's own baseline levels, may provide greater predictive value than single-timepoint inter-patient comparisons.

Moving beyond immune checkpoint inhibitors (ICI), targeting DLL3 with tarlatamab in previously treated ES-SCLC generated an unprecedented response...Due to tumor heterogeneity and plasticity, rational combinations pursuing broader cancer cell vulnerabilities are likely necessary in the future to prevent relapse. Better tools for response monitoring are urgently needed to gauge progress.

Transcriptomics analyses were performed to investigate the effect of the deletion of the ArpA-like gene sclM4 on the expression of the scl biosynthetic genes, shedding light on the role of the corresponding transcriptional repressor. The present work improves understanding of scleric acid biosynthesis and provides new insights into the ArpA-like mediated regulation of biosynthetic gene expression in Streptomyces bacteria.